Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The language in S. 1913 now included as part of S. 524 strikes the appropriate balance of prospectively identifying at-risk beneficiaries and help them obtain the necessary treatment sooner to address addictions potential abuse while simultaneously preserving a beneficiaries’ rights to be notified, submit their preferences for prescriber and pharmacy, and exercise appeals.
On March 8, 2016, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “Medicare Program; Part B Drug Payment Model1” under the authority of section 1115A of the Social Security Act and the Centers for Medicare and Medicaid Innovation (CMMI).
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2017 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2017 Call Letter” released on February 19, 2016.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to submit comments for the record on the hearing titled “Examining the Opioid Epidemic: Challenges and Opportunities” scheduled for February 23, 2016. AMCP supports a holistic, comprehensive, and multi-stakeholder approach among health care providers and patients that truly addresses the opioid epidemic.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to submit comments for the record on the hearing titled “Examining Implementation of the Biologics Price Competition and Innovation Act” scheduled for February 4, 2016.
The Academy of Managed Care Pharmacy (AMCP) commends the Obama Administration and the Centers for Medicare and Medicaid Services (CMS) for its support of Senator Pat Toomey’s (R-PA) leadership in addressing the opioid epidemic and S. 1913 - “The Stopping Medication Abuse and Protecting Seniors Act.”
The Academy of Managed Care Pharmacy (AMCP) is opposed to the Substitute for House Bill 4812 because the U.S. Food and Drug Administration (FDA) has not released guidance on how applicants can demonstrate interchangeability.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Disease Control and Prevention (CDC) for its work in developing strategies to address the growing opioid epidemic in the United States and for the opportunity to provide comments in response to the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain (CDC-2015-0112).
The Academy of Managed Care Pharmacy (AMCP) is pleased to provide general comments and recommendations to the Call for Comments on Endorsement Consideration by PQA Members of a New Performance Measure: Adherence to Long-Acting Inhaled Bronchodilator Agents in COPD Patients.
